SAPIEN 3 Ultra RESILIA valve shows significant 1-year benefits, including lower all-cause mortality (driven by lower PVL), stroke, and bleeding compared to earlier models. Strong indications for ...
Q4 2024 Earnings Call Transcript February 11, 2025 Edwards Lifesciences Corporation beats earnings expectations. Reported EPS ...
Edwards Lifesciences reports strong contributions from all product groups ??? TAVR, TTMT and surgical structural heart ??? in ...
Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter and full-year ended Dec. 31, 2024. Highlights and Outlook Q4 sales grew 9% to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback